ATLANTA, May 27, 2026 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Gossamer Bio, Inc. (“Gossamer Bio” or the “Company”) (NASDAQ: GOSS). The lawsuit alleges that Defendants issued false and misleading statements and/or failed to disclose material adverse facts regarding Gossamer Bio’s study design for its Phase 3 PROSERA study, particularly with respect to controlling for the placebo response at the Latin American testing sites. If you purchased Gossamer Bio shares between Ju ...